Latest results FY2026 · Prices updated Oct 30, 2026
HQ: Kyoto, KyotoFounded 19191,876 employeesWebsite
A mid-sized pharmaceutical company specializing in urology, hematology, and rare diseases. It developed the world's first treatment for Duchenne muscular dystrophy and also operates a functional food business.
Business segments (share of revenue)
Latest results
FY2026
vs. same period a year earlier
Company forecastFY2027
| Segment | Share | Revenue | Operating profit | Margin |
|---|---|---|---|---|
| Pharmaceutical Business | 87% | ¥148.5B | ¥33.3B | 22.5% |
| Functional Food Business | 13% | ¥22.3B | ¥857M | 3.8% |
Close (Oct 30, 2026)
¥3,436+6.8% (1Y)
Nippon Shinyaku +6.8% over 1Y, 6.0pt below the industry average (23 companies, +12.8%).
Reference chart of daily closing prices, not real-time quotes (split-adjusted; weekly closes before the last year). Updated Oct 30, 2026.
| Period | Revenue | Op. profit | Net income | Total assets | Revenue YoY |
|---|---|---|---|---|---|
| 2026FY | ¥170.8B | ¥35.5B | ¥29.7B | ¥346.4B | +6.6% |
| 2025FY | ¥160.2B | ¥35.5B | ¥32.6B | ¥283.6B | +8.1% |
| 2024FY | ¥148.3B | ¥33.3B | ¥25.9B | ¥263.4B | +2.8% |
| 2023FY | ¥144.2B | ¥30.0B | ¥22.8B | ¥237.5B | +4.9% |
| 2022FY | ¥137.5B | ¥32.9B | ¥25.0B | ¥219.9B | +12.8% |
| 2021FY | ¥121.9B | ¥27.2B | ¥19.5B | ¥205.4B | — |
Sources: annual securities reports, earnings releases and other public disclosures (Dec 2024)
Data may contain input errors. For reference only; we accept no responsibility for its accuracy.
